Navigation Links
Amgen Backs States' Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
Date:1/25/2013

THOUSAND OAKS, Calif., Jan. 25, 2013 /PRNewswire/ -- In conjunction with our oncology biosimilars partner Actavis' announcement earlier today of our four oncology biosimilars products, Amgen (NASDAQ: AMGN) today stated that it supports state biosimilars initiatives that focus on sound science and patient safety. As a biotech company developing both innovator biologics and biosimilars, Amgen believes that patient safety does not stop at drug approval. 

"Amgen endorses state policies that would put patients first and, in doing so, increase confidence in the biosimilar pathway. It is important to have consistent policies in place at the federal and state level," said Scott Foraker , vice president and general manager of biosimilars at Amgen. 

States' efforts to create safe substitution rules for interchangeable biologics will help accelerate the successful implementation of the U.S. biosimilars pathway. Regulatory authorities in Europe and the U.S. have emphasized the need for long-term safety monitoring of biologics. Biologic medicines are different than traditional chemical drugs in several important ways. Biologics are so complex that they can usually only be made by a living cell.  In fact, when made by different manufacturers, they differ from each other.  They are also very large compared to chemical drugs and can be more sensitive to storage and handling. As a result biologic medicines have the potential to cause an unwanted immune response, which can show up months after taking the medicine. This emphasizes why Amgen believes state pharmacy acts must enhance safety monitoring of substituted biologics.

Amgen is helping educate state policymakers on these considerations to ensure that physicians, patients and pharmacists share important in
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgens Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
2. Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
3. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
4. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
5. Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
6. Amgen Supports Assistance for Patients Affected by Hurricane Sandy
7. Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
8. Amgen To Present At The Morgan Stanley Global Healthcare Conference
9. Amgen To Present At The Baird Healthcare Conference
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
Breaking Medicine Technology:12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... Company, Limited (hereafter, Daiichi Sankyo), announced today that the ... (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 ... Welfare in Japan. Edoxaban, which is being ... anticoagulant that specifically, reversibly and directly inhibits the enzyme, ...
... Ontario, April 21, 2011 Valeant Pharmaceuticals International, Inc. ... the following statement to shareholders of Cephalon, Inc. (NASDAQ: ... today, the Cephalon Board of Directors stated that it ... Company,s alternatives and options – and is focused on ...
Cached Medicine Technology:Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 2Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 3Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 4Valeant Pharmaceuticals Responds to Cephalon Board's Letter 2Valeant Pharmaceuticals Responds to Cephalon Board's Letter 3Valeant Pharmaceuticals Responds to Cephalon Board's Letter 4
(Date:8/30/2015)... ... August 30, 2015 , ... Natural Rest contains a ... as sleep aids and calming remedies, which help to improve mood disorders and anxiety. ... great deal of research in the field of regenerative medicine conducted by Dr. Amit ...
(Date:8/29/2015)... ... 2015 , ... Rio Salado College President Chris Bustamante announced on ... of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado for the ... and impact through innovative technologies and strategies. , “I am very proud to be ...
(Date:8/29/2015)... ... August 29, 2015 , ... It ... and protection against dribbled urine and sweat. "In order to prevent these problems, ... The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/28/2015)... (PRWEB) , ... August 29, 2015 , ... Rio ... higher learning and the student experience as part of the EDUCAUSE - Next Generation ... Foundation . , This is the third Breakthrough Models Incubator hosted by ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... AMD Global Telemedicine Inc., Director of Clinical training, Diane Castelli appointed ... , ... North Chelmsford, MA (PRWEB) May 22, 2009 -- ... been elected by her colleagues to chair the American Telemedicine Association,s ...
... Associates, Inc., OMMA Healthcare, LLC and Medical Equipment ... supported by OMMA,s Middle East division, OMMA Projects-Middle ... Al Nidhal Construction. The Governorate of Baghdad selected ... Iraqi Hospital, Al Nahrein Hospital, previously Al Rasheed ...
... viruses with key toxicities removed, providing a new ... better vaccines for a broad range of viral ... of mRNA in different cell types, and this ... for cell-specific inactivation. Cancer Research UK scientists at ...
... Vega Tapped to Lead Health Care Improvement Firm,s ,Sales, Marketing Efforts ... ... today announced the addition of Al Vega as senior vice president and ... time of continued growth and will be responsible for driving sales and ...
... Delivery of PMTCTGENEVA, May 21 In a dramatic ... of the International Treatment Preparedness Coalition (ITPC) and AIDS-Free ... members of UNAIDS and WHO to present ITPC,s latest ... Failing Children: HIV, Vertical Transmission and Women,s Health, ...
... AFL ) announced today that it will make ... Conference. Chairman and Chief Executive Officer Daniel P. Amos ... a presentation on May 27, 2009, at 4:00 p.m. EDT. ... the company,s outlook for 2009 and its strategy for growth ...
Cached Medicine News:Health News:AMD Global Telemedicine Inc., Proud to Announce Diane Castelli, Chair of the American Telemedicine Association's (ATA) Telehealth Nursing Special Interest Group (SIG) 2Health News:An International Design Team has Been Selected for an Iraqi Hospital to Transform Healthcare in the Middle East 2Health News:MicroRNA regulation of tumor-killing viruses avoids unwanted viral pathology 2Health News:Press Ganey Names Chief Sales and Marketing Officer 2Health News:AIDS Treatment Activists Push UNAIDS and WHO to Meet Commitments to Reduce HIV in Women and Newborns 2Health News:AIDS Treatment Activists Push UNAIDS and WHO to Meet Commitments to Reduce HIV in Women and Newborns 3Health News:Aflac Incorporated to Present at the Sanford Bernstein 25th Annual Strategic Decisions Conference 2
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... System is a latex-free unisex system ... simple catheterization designed to reduce the ... It includes a 100% latex-free Mentor ... tear tab makes it easy to ...
... Self-Cath Closed System is a latex-free ... for safe, simple catheterization designed to ... infections. It includes a 100% ... new EasyOff tear tab makes it ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
Medicine Products: